share_log

8-K: Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

8-K: Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

8-K：Cingulate公布2024年第一季度财务业绩并提供临床和业务最新情况
美股sec公告 ·  05/08 07:13
Moomoo AI 已提取核心信息
On May 8, 2024, Cingulate Inc., a biopharmaceutical company, announced its financial results for the first quarter of 2024. The company, which specializes in Precision Timed Release™ drug delivery technology, reported a net loss of $3.0 million for the quarter, a decrease from the $4.0 million loss in the same period of the previous year. This reduction in net loss was attributed to decreased research and development (R&D) and general and administrative (G&A) expenses. R&D expenses dropped due to increased clinical activity offset by lower manufacturing and personnel costs, while G&A expenses fell primarily due to reduced personnel and insurance expenses. Cingulate also highlighted the progress of CTx-1301, its lead product candidate for the treatment of ADHD, which is on track...Show More
On May 8, 2024, Cingulate Inc., a biopharmaceutical company, announced its financial results for the first quarter of 2024. The company, which specializes in Precision Timed Release™ drug delivery technology, reported a net loss of $3.0 million for the quarter, a decrease from the $4.0 million loss in the same period of the previous year. This reduction in net loss was attributed to decreased research and development (R&D) and general and administrative (G&A) expenses. R&D expenses dropped due to increased clinical activity offset by lower manufacturing and personnel costs, while G&A expenses fell primarily due to reduced personnel and insurance expenses. Cingulate also highlighted the progress of CTx-1301, its lead product candidate for the treatment of ADHD, which is on track for a Marketing Approval filing with the FDA in the first half of 2025. The company raised $10.7 million in capital and converted $3.3 million of debt to equity in 2024. As of March 31, 2024, Cingulate had $1.1 million in cash and cash equivalents, with total liabilities decreasing to $2.3 million and stockholders' equity increasing by $10 million to $3.2 million.
2024年5月8日，生物制药公司Cingulate Inc. 公布了其2024年第一季度的财务业绩。该公司专门从事Precision Timed Release™ 药物递送技术，报告本季度净亏损300万美元，低于去年同期的400万美元亏损。净亏损的减少归因于研发（R&D）以及一般和管理（G&A）支出的减少。研发费用下降是由于临床活动的增加被较低的制造和人员成本所抵消，而G&A支出下降的主要原因是人员和保险费用的减少。Cingulate还强调了其治疗注意力缺陷多动障碍的主要候选产品CTx-1301的进展，该产品有望在2025年上半年向美国食品药品管理局申请上市许可。该公司在2024年筹集了1,070万澳元的资本，并将330万澳元的债务转换为股权。截至2024年3月31日，Cingulate拥有110万美元的现金及现金等价物，总负债减少至230万美元，股东权益增加了1000万美元，至320万美元。
2024年5月8日，生物制药公司Cingulate Inc. 公布了其2024年第一季度的财务业绩。该公司专门从事Precision Timed Release™ 药物递送技术，报告本季度净亏损300万美元，低于去年同期的400万美元亏损。净亏损的减少归因于研发（R&D）以及一般和管理（G&A）支出的减少。研发费用下降是由于临床活动的增加被较低的制造和人员成本所抵消，而G&A支出下降的主要原因是人员和保险费用的减少。Cingulate还强调了其治疗注意力缺陷多动障碍的主要候选产品CTx-1301的进展，该产品有望在2025年上半年向美国食品药品管理局申请上市许可。该公司在2024年筹集了1,070万澳元的资本，并将330万澳元的债务转换为股权。截至2024年3月31日，Cingulate拥有110万美元的现金及现金等价物，总负债减少至230万美元，股东权益增加了1000万美元，至320万美元。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息